| Company Name: |
SynZeal Research Pvt Ltd
|
| Tel: |
+1 226-802-2078 |
| Email: |
standards@synzeal.com |
| Products Intro: |
Product Name:Miglustat
|
| Company Name: |
MYLAN API US LLC
|
| Tel: |
080 6672 8000 |
| Email: |
jane.doe@mylan.com |
| Products Intro: |
Product Name:MIGLUSTAT
|
|
| | Miglustat Basic information |
| Product Name: | Miglustat | | Synonyms: | Miglustat | | CAS: | | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Miglustat Structure]() |
| | Miglustat Chemical Properties |
| | Miglustat Usage And Synthesis |
| Description | This orally active glucosylceramide glucosyltransferase
inhibitor, was launched for the treatment of type I Gaucher’s
disease. Miglustat (XVI) has been developed and
launched by Oxford GlycoSciences (OGS; now Celltech) and
Actelion. | | Uses | Treatment of glycolipid storage diseases. | | Brand name | Zavesca(Actelion). | | Synthesis | Miglustat was originally discovered at Searle (now
Pfizer) and an enzymatic oxidation was employed in the
synthesis. D-Glucose (125) was subjected to reductive
amination with n-butylamine in ethanol under 4 atm of
hydrogen in the presence of Pd/C catalyst at 60 oC to give
N-butylglucamine HCl salt (126) in 90% yield. Nbutylglucamine
(126) then was submitted to a selective
microorganism oxidation by Gluconobacter Oxidans (DSM
2003) cell paste in water to give 6-(butylamino)-6-deoxy-a-
L-sorbofuranose HCl salt (127) in 80 % yield. Finally,
compound 127 was cyclized and reduced in situ with
hydrogen over Pd/C at 4000 atm in ethanol/water to give
miglustat (XVI) in 45% overall yield from D-glucose (125). 
|
| | Miglustat Preparation Products And Raw materials |
|